GU Cancers 2021 | 18F-fluciclovine PET in mCRPC treated with abiraterone acetate
Pedro Barata, MD, MSc, Tulane University School of Medicine, New Orleans, LA, discusses the use of 18F-fluciclovine positron emission tomography (PET) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate. PET imaging has been shown to be superior in the detection of prostate cancer compared to conventional computed tomography (CT) and bone scans. 18F-Fluciclovine is upregulated to a greater extent in prostate cancer cells than in surrounding tissue. A pilot study (NCT04158245) will describe changes in 18F-Fluciclovine PET and compare these results with prostate-specific antigen (PSA) to determine the extent of correlation, and conventional computerized tomography (CT) and bone scans to assess disease monitoring efficacy in mCRPC patients treated with abiraterone acetate plus prednisone. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Pedro Barata, MD, MSc, has served in a consulting or advisory role for Bayer, Bristol-Myers Squibb, Pfizer, EMD Serono, Eisai, Caris Life Sciences, Clovis, and Dendreon; and has received institutional research funding from Blue Earth Diagnostics, AstraZeneca and Merck.
